#United States #Washington #Cancer Research #small cell lung cancer #LUNGevity Foundation

LUNGevity Foundation Introduces New Research Program for Small Cell Lung Cancer

The LUNGevity Foundation, the leading organization in lung cancer advocacy and research, has launched an ambitious multi-year initiative aimed at tackling the challenges faced by patients with small cell lung cancer (SCLC). This initiative is particularly significant, given that SCLC represents one of the most aggressive forms of lung cancer and has historically been underserved in terms of treatment options and research funding.

During recent oncology conferences, including the ASCO Annual Meeting and the IASLC World Conference on Lung Cancer, remarkable advancements in SCLC treatments were revealed. Early studies highlighted promising new antibody-drug conjugates (ADCs) and DLL3-targeted CAR T-cell therapies that show potential in treating relapsed conditions. Notably, two phase 3 trials presented at the IASLC conference demonstrated that B7-H3-targeted ADCs can significantly extend the lives of patients who have failed standard treatments like topotecan. Furthermore, results from the phase 3 DeLLphi-305 trial showcased how adding tarlatamab to durvalumab improved survival rates for patients in the first line of extensive-stage SCLC treatment, marking a significant breakthrough in the field.

These groundbreaking developments not only signal new hope for the estimated 30,000 to 35,000 Americans diagnosed with SCLC each year but also introduce new complexities in therapeutic management. As therapies increasingly employ advanced immune-based mechanisms and targeted delivery, there arises a necessity for careful monitoring of side effects and strong collaboration between oncology specialists and community healthcare providers. The LUNGevity Foundation recognizes the urgency of addressing these needs to ensure that all patients benefit from these scientific advancements.

To facilitate this, the foundation's new initiative encompasses five carefully coordinated projects designed to understand and mitigate barriers faced by SCLC patients at multiple levels, including individual patient experiences, healthcare provider practices, and systemic healthcare infrastructure. Key components of the initiative include:

1. Comprehensive Patient Documentation: Understanding how patients with extensive-stage SCLC navigate their diagnosis and treatment regimens.
2. AMPLIFY Study: Conducting research to ascertain which treatment benefits and drawbacks matter most to patients and their caregivers, allowing for more informed care decisions aligned with patient priorities.
3. Project Lighthouse: Working directly with community oncology practices to create accessible pathways for every eligible SCLC patient to receive innovative therapies.
4. Survivorship Programs: Translating research findings into educational resources, maintaining a living database for clinical trials, and providing peer support systems.
5. Coalition Building: Forming a coalition among key stakeholders to establish and disseminate best practices that adapt to ongoing drug approvals and therapies.

Andrea Ferris, President and CEO of LUNGevity Foundation, emphasized the importance of this initiative, stating, "For too long, a diagnosis of small cell lung cancer meant limited choices. Today’s research and advancements bring new hope to those living with this form of cancer. However, scientific breakthroughs are meaningless unless they directly reach the patients who need them." She also expressed gratitude for initial support from AMGEN, underscoring the collaborative effort needed to establish a strong community surrounding small cell lung cancer.

Patients seeking information about treatments, clinical trials, and survivor support can visit sclc.lungevity.org or contact LUNGevity's specialized HELPLine. As LUNGevity enhances their mission of advocating for lung cancer patients, it remains focused on bridging the gap between clinical science and patient-focused care, ensuring that every person affected by small cell lung cancer can access the best possible treatment and support.

About LUNGevity Foundation

LUNGevity Foundation is transforming the landscape of lung cancer diagnosis and care. By engaging in research, advocacy, and patient support, it fosters connections that can drive essential progress. As the largest nonprofit funder of lung cancer research across the United States, LUNGevity is committed to enhancing early detection methods, improving treatment efficacy, and nurturing the next generation of researchers. The organization empowers patients and caregivers with reliable information, resources, and robust advocacy for increased access to necessary treatments and quality care.

For more information on LUNGevity’s initiatives and support services, please visit www.LUNGevity.org.